John Gierula
Chronic heart failure (CHF), which frequently affects a large portion of the global population, frequently progresses to a life-threatening condition, and has a high mortality rate, is another significant global public health issue. The most recent developments in the treatment of CHF patients whose left ventricular ejection fraction (LVEF) is less than 40% interest us. In recent years, cardiac disease etiology has been linked to BNP. Since sacubitril and aspirin, an angiotensin receptor neprilysin inhibitor, were part of a complex medical treatment plan for CHF patients, we decided to investigate their effects. In addition, we looked into the treatments, particularly cardiac resynchronization therapy, that were used to treat these patients with the device. Last but not least, we compared the outcomes of cardiac resynchronization therapy to those of a sophisticated medical treatment plan that included sacubitril and valsartan, both of which are angiotensin receptor neprilysin inhibitors.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 